Jun 19, 2018

Will the Theranos scandal put a damper on medical tech investing?

HTML EMBED:
COPY

The blood-testing startup Theranos is now firmly in disgrace. Founder Elizabeth Holmes was indicted Friday on federal wire fraud charges and has resigned as the company’s CEO. But whatever happens with Holmes and Theranos, the episode has changed the conversation…

Segments From this episode

Will the Theranos scandal put a damper on medical tech investing?

Jun 19, 2018
It's become a cautionary tale for biotech investors. Are they heeding it?
Elizabeth Holmes speaks during the closing session of the Clinton Global Initiative 2015 in New York City.
JP Yim/Getty Images

The blood-testing startup Theranos is now firmly in disgrace. Founder Elizabeth Holmes was indicted Friday on federal wire fraud charges and has resigned as the company’s CEO. But whatever happens with Holmes and Theranos, the episode has changed the conversation around biotech investing. Michael Greeley is general partner of Flare Capital Partners in Boston, which specializes in funding health care technology companies. He spoke with Marketplace Tech host Molly Wood about what the Theranos downfall means to the industry overall. (06/19/2018)

Listening makes you smarter…
donating makes it all possible.

Our mission is to raise the economic intelligence of the country, exploring the intersection of the economy, tech, and our daily lives. As a nonprofit news organization, we count on your support – now more than ever before.

Secure the future of public service journalism today when you become a Marketplace Investor.